Biotech sector is getting hot, especially for companies connected to COVID-19 vaccine and treatments development... BIOV chart looks rip for a breakout with MACD closing in on bullish cross and a major catalyst in the form of FDA approval of its Phase I/II study:
FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical...
KNR has been beaten down but looks way overdone, given they have just raised $8.5 at 1.50 with institutional investors. The company reported respectable $3.3M revenues in Q1 2021. Their BioCloud COVID-19 detection device will be used by the Canadian Olympic delegation at the Tokyo Olympics. The US sales channel is being worked on. Insiders are buying in the open...
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
Expanding existing COVID-19 vaccine research collaboration which began in July 2020.
Medytox and Dyadic to co-develop C1 enabled COVID-19 vaccines and/or boosters which will immunize people against two or more of the current and future COVID-19 variants (e.g., tetravalent or quadrivalent COVID-19...
SuperCom Wins COVID-19 Quarantine Compliance Project with the Israeli Government Valued at an Estimated $3 Million per Month in Recurring Revenues
Initial project term of 3 months, with potential extension for up to 36 months
This nationwide project is expected to commence next week, along with contract signing, for an initial term of 3 months, with an option to...
The 55-day moving average broke down, just the 99-day moving average has remained to lift off.
with the positive result of the COVID-19 vaccine trial, everything is possible.
T2 Biosystems T2SARS-CoV-2™ Panel Proves Capable of Detecting the Brazil P.1 Variant of the SARS-CoV-2 Virus
Panel is capable of detecting 99.99% of all currently identified SARS-CoV-2 viruses based on sequence alignments and in silico analysis.
finance.yahoo.com
TYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections
TYME announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating...
Aeterna Zentaris Announces Evaluation and Potential Development of an Oral Prophylactic Bacterial Vaccine Against COVID-19 Through Exclusive Option Agreement with Julius-Maximilians-University Wuerzburg
- Company secures next step to continue to build-out pipeline of assets.
- University researchers developed a proprietary and orally active bacterial vaccine...
Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19
announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19).
The submission of the IND to FDA followed a Pre-IND meeting with FDA in which FDA gave specific...
VST has its hand in a number of sectors, including a sizeable holding in FANS (esports/gambling stock) but it has recently gained attention because of its stake in the rapid COVID-19 test manufacturer. Yesterday, they've announced that they are increasing their manufacturing capacity by 5M test kits per month. In the followup webinar, investors were informed of...
I don't actually like Gilead Sciences for a long-term buy and hold, because its earnings have been in a long-term downtrend. There's a case to be made for a swing trade, however. Gilead is now sitting on trend line support in a fairly high-volume range. It's about 25% below its median forward P/E and forward P/S for the last three years. It has been selling off on...
We've now had five early earnings reports from the consumer staples sector in the last couple weeks, including today's reports from General Mills and Constellation Brands. On average, EPS for these companies beat analyst estimates by 12.5%, revenue beat by over 3%. That suggests that analysts have underestimated both demand and profit margins for this sector in...
On May 15, 2020, Sorrento had this to say about the COVID-19 vaccine they are working on...
“We’re actually so impressed with the data,” Ji said. “One of the antibodies is so powerful that at a very low concentration it is able to 100% completely prevent infection or inhibit the infection. In our studies, not even one virus escaped from the antibody.”
"Phase 1...
Long on PK! Breakout to the next Daily Moving Average.
COVID - 19 Vaccian developments with very promising news + The fed will support the industry with infinite money.
Dividend Yield post covid-19 will be about 15% Annually.
The price is stable with low volatility.
The company has enough cash to operate for 18 months, and they will issue a bond to raise more...
